Analysts Have Made A Financial Statement On Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) First-Quarter Report

As you might know, Glenmark Pharmaceuticals Limited (NSE:GLENMARK) recently reported its quarterly numbers. It was a workmanlike result, with revenues of ₹40b coming in 2.6% ahead of expectations, and statutory earnings per share of ₹48.24, in line with analyst appraisals. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Following the recent earnings report, the consensus from ten analysts covering Glenmark Pharmaceuticals is for revenues of ₹168.0b in 2027. This implies a measurable 5.3% decline in revenue compared to the last 12 months. Per-share earnings are expected to soar 30% to ₹82.99. In the lead-up to this report, the analysts had been modelling revenues of ₹166.7b and earnings per share (EPS) of ₹83.33 in 2027. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

View our latest analysis for Glenmark Pharmaceuticals

The analysts reconfirmed their price target of ₹2,501, showing that the business is executing well and in line with expectations. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic Glenmark Pharmaceuticals analyst has a price target of ₹2,750 per share, while the most pessimistic values it at ₹2,100. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Glenmark Pharmaceuticals is an easy business to forecast or the the analysts are all using similar assumptions.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 7.0% by the end of 2027. This indicates a significant reduction from annual growth of 7.2% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 12% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Glenmark Pharmaceuticals is expected to lag the wider industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Glenmark Pharmaceuticals' revenue is expected to perform worse than the wider industry. The consensus price target held steady at ₹2,501, with the latest estimates not enough to have an impact on their price targets.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for Glenmark Pharmaceuticals going out to 2029, and you can see them free on our platform here.

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Glenmark Pharmaceuticals that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.